Sullivan Christopher Ryan has filed 18 insider transactions across 1 company since February 2023.
Most recent transaction: a sale of 500 shares of Avalo Therapeutics, Inc. ($AVTX) on April 01, 2026.
Activity breakdown: 1 open-market purchase and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | S | Common Stock | 500 | $15.86 | 32,797.0000 | 18,133,968 | 1.50% | 0.00% |
| April 2, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | S | Common Stock | 1780 | $17.57 | 17,338.0000 | 18,133,968 | 9.31% | 0.01% |
| April 2, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | S | Common Stock | 6200 | $17.02 | 19,118.0000 | 18,133,968 | 24.49% | 0.03% |
| April 1, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | S | Common Stock | 7479 | $16.83 | 25,318.0000 | 18,133,968 | 22.80% | 0.04% |
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | M | Common Stock | 24200 | $0.00 | 41,538.0000 | 18,133,968 | 139.58% | 0.13% |
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | M | Restricted Stock Units | 24200 | $0.00 | 24,200.0000 | 18,133,968 | 50.00% | 0.13% |
| March 28, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | F | Common Stock | 8241 | $13.89 | 33,297.0000 | 18,133,968 | 19.84% | 0.05% |
| Feb. 26, 2026 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | A | Stock Option (Right to Buy) | 105000 | $0.00 | 105,000.0000 | 18,133,968 | 9999.99% | 0.58% |
| Dec. 10, 2025 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | F | Common Stock | 155 | $4.10 | 17,338.0000 | 18,133,968 | 0.89% | 0.00% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | M | Common Stock | 24200 | $0.00 | 24,206.0000 | 10,671,934 | 9999.99% | 0.23% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | M | Restricted Stock Units | 24200 | $0.00 | 48,400.0000 | 10,671,934 | 33.33% | 0.23% |
| March 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | F | Common Stock | 7285 | $8.46 | 16,921.0000 | 10,671,934 | 30.10% | 0.07% |
| Jan. 28, 2025 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | A | Stock Option (Right to Buy) | 163000 | $0.00 | 163,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 13, 2024 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | A | Restricted Stock Units | 72600 | $0.00 | 72,600.0000 | 0 | 9999.99% | 0.00% |
| Aug. 13, 2024 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | A | Stock Option (Right to Buy) | 186700 | $0.00 | 186,700.0000 | 0 | 9999.99% | 0.00% |
| June 9, 2023 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | P | Common Stock | 511 | $3.42 | 1,262.0000 | 0 | 68.04% | 0.00% |
| May 15, 2023 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 13, 2023 | Avalo Therapeutics, Inc. | $AVTX | Sullivan Christopher Ryan | Chief Financial Officer | A | Stock Option (Right to Buy) | 40000 | $0.00 | 40,000.0000 | 0 | 9999.99% | 0.00% |